Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(5R)-5-{[(2-Amino–3H-purin–6‑yl)oxy]methyl}‑2‑pyrrolidinone is a synthetic small molecule and an O^6-substituted guanine derivative. It contains a purine base structure similar to guanine, with a pyrrolidinone ring attached via an ether linkage at the 6-position of the purine. The compound is classified as experimental and has not been approved for any therapeutic use or clinical indication. Its mechanism of action is not well characterized, but it may be used in biochemical research as a nucleoside analog or for studying interactions with enzymes such as cyclin-dependent kinase 2 (CDK2), based on its structural similarity to known ligands. No clinical trials or approved indications are reported.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (5R)-5-{[(2-Amino-3H-purin-6-yl)oxy]methyl}-2-pyrrolidinone.